Tower Research Capital (TRC)’s Parabilis Medicines Inc PBLS Stock Holding History

Tower Research Capital (TRC)’s Portfolio PBLS Stock Details PBLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$56.7K	Buy	+2,070	New	+$57.2K	﹤0.01%	2630

Other funds holding PBLS

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Tower Research Capital (TRC)'s PBLS Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Parabilis Medicines Inc (PBLS) in Q2 2026: 2,070 shares worth $56.7K. The stake represents ﹤0.01% of the portfolio and ranks #2630 among its holdings.

79 funds tracked by Wall St. Rank hold PBLS as of Q2 2026.

Tower Research Capital (TRC) held 2,070 shares of Parabilis Medicines Inc worth $56.7K as of Q2 2026.
Parabilis Medicines Inc was a new Tower Research Capital (TRC) position in Q2 2026.
Parabilis Medicines Inc made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2630 holding.
79 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.